Oncology Animal Models
Oncology Animal Model Services
Pharmaron proudly provides unparalleled expertise in supporting drug discovery through cutting-edge oncology animal model services. Our team brings a wealth of experience, making us a trusted oncology CRO in the industry.
We know that timing is essential. Therefore, Pharmaron provides results in excellent turnaround times, including short lead times for study initiation, prompt quoting, timely updates on study progress, and access to our in-house biomarker and bioanalysis capabilities.
Direct Assess to Large Tumor Model Library
With an extensive library of over 1,700 tumor models, we ensure our clients have access to the ideal model for their specific research needs without delays. We offer many models, including xenografts and syngeneic tumor models for advanced immuno-oncology studies.
Innovation through Innovative Oncology Animal Models
Our teams are at the forefront of innovation, helping our clients investigate mechanisms of drug resistance and support the discovery of cancer targets through the creation of genetically modified tumor models and in vivo CRISPR screening programs.
Large Modality Coverage for Animal Testing
Modality-specific expertise is needed to select the right oncology animal models, dosing strategies, biomarkers, bioanalysis, and endpoints. Our teams have long-standing expertise in small molecules, biologics, conjugates, oligonucleotides, peptides, radiotherapeutics, as well as cell and gene therapies.
Study Types:
- Development and validation of disease models
- Maximum tolerated dose studies
- Dose range finding studies
- Efficacy screening studies
- in vivo CRISPR screening
- X-ray radiation studies
- PK/PD studies
Capabilities
Tumor Models
- Large cancer cell line (2,300+) and tissue bank
- 1,200+ fully validated cell-line-derived xenograft (CDX) models
- 110+ syngeneic tumor models with complete immune profile and SOC data
- 350+ patient-derived xenograft (PDX) models with patient history and exome-seqence as well as oncogene panel
- CDX and PDX organoids platform including immune cell co-cultures for immunotherapy testing
- 190+ orthotopic models of more than 15 cancer types, including intracranial implantation
- Genetically engineered oncology animal models
- Drug-resistant tumor models
- Humanized tumor models based on human CD34+ hematopoietic stem cells
ex vivo Testing Expertise
Comprehensive ex vivo testing capabilities are part of our oncology CRO service, providing critical insights to interpret oncology animal studies.
Our capabilities include the analysis of blood, tissue, and, in many cases, other body fluids, including urine and feces.
- Bioanalysis capabilities to quantify drug exposure
- Biomarker and immune profiling
- Omics platform for various species and tissue types, covering bulk RNAseq, single-cell RNA–sequencing, whole exome sequencing and whole genome sequencing
- Protein analysis platforms, including mass spectrometry and various multiplex platforms
- Flow cytometry and cell sorting
- Histology and IHC
- Blood biochemistry and hematology
Learn more about Pharmaron’s Oncology and Immuno-Oncology Capabilities
Research Case Studies Showcasing Pharmaron’s Oncology Animal Models
in vivo CRISPR study to identify novel therapeutic cancer drug targets
A study on X-ray radiation therapy across various mouse tumor models
Leveraging IVIS imaging techniques for drug potency testing
